Business Context and Reporting Period
Company: BioSig Technologies, Inc. (Note: Input metadata referenced "Streamex Corp.", but the filing text identifies the registrant as BioSig Technologies, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: BioSig is a medical device company developing the PURE EP System for cardiac arrhythmia treatment. The company operates through three segments: BioSig Technologies (parent), ViralClear Pharmaceuticals, and BioSig AI Sciences. The company is in an early commercialization stage with minimal revenue and significant accumulated deficits.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2024 | Nine Months Ended Sept 30, 2024 | Balance Sheet (Sept 30, 2024) |
|---|---|---|---|
| Total Revenue | $0 | $27,000 | N/A |
| Net Loss (Attributable to Common) | $(1,940,000) | $(9,395,000) | N/A |
| Operating Expenses | $2,950,000 | $11,706,000 | N/A |
| Cash and Equivalents | N/A | N/A | $615,000 |
| Working Capital | N/A | N/A | $(853,000) Deficit |
| Total Assets | N/A | N/A | $1,418,000 |
| Total Liabilities | N/A | N/A | $1,701,000 |
| Accumulated Deficit | N/A | N/A | $(254,246,000) |
Note: All figures in thousands except per share data. Revenue is derived primarily from service contracts and lease components.
Material Changes vs. Prior Period
- Revenue: Revenue for the three months ended Sept 30, 2024, was $0 compared to $1,000 in the prior year period. For the nine months, revenue increased to $27,000 from $6,000 in the prior year.
- Net Loss: Net loss attributable to common shareholders decreased significantly to $(1.94) million for the quarter (from $(4.57) million) and $(9.40) million for the nine months (from $(23.00) million). This improvement is largely due to a non-cash gain on the settlement and forgiveness of accounts payable of $1.02 million (quarter) and $2.41 million (nine months).
- Operating Expenses: Total operating expenses decreased to $2.95 million for the quarter (from $4.05 million) and $11.71 million for the nine months (from $22.35 million). This reduction is attributed to significant workforce reductions in early 2024 and decreased R&D spending.
- Asset Impairment: The company recorded a $253,000 impairment charge on long-term assets during the nine months ended Sept 30, 2024, due to reduced manufacturing activity. No such charge was recorded in the prior year period.
- Stock-Based Compensation: Stock-based compensation expense increased in the current period compared to the prior year, driven by new grants to consultants and board members.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows from operations ($4.28 million used in nine months), and a working capital deficit. Continued operations depend on raising additional capital.
- Liquidity Strategy: Management plans to reduce cash burn by shifting focus to business development and partnerships rather than internal manufacturing. The company currently has 5 employees and 6 key consultants.
- Unusual Items:
- Debt Forgiveness: A significant gain of $2.41 million was recognized from the settlement and forgiveness of accounts payable.
- Preferred Stock Dividend: A non-cash deemed dividend of $157,000 was recorded due to a reset in the conversion price of Series C Preferred Stock.
- Listing Status: The company was delisted from Nasdaq in June 2024 but regained compliance and resumed trading on the Nasdaq Capital Market in October 2024. It currently has a 180-day compliance period to maintain the $1.00 minimum bid price.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, specifically regarding stock-based compensation identification, period-end review processes, and segregation of duties.
- Acquisition Intent: The company executed a non-binding Letter of Intent to acquire assets of Neuro-Kinesis Corporation, potentially receiving $2.5 million to $6 million in cash at closing.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $615,000 cash balance against the current burn rate and the timeline for securing additional financing.
- Debt Settlement Validity: Confirm the terms and finality of the accounts payable forgiveness that generated the $2.4 million gain.
- Nasdaq Compliance: Monitor the company's ability to maintain the $1.00 minimum bid price during the 180-day compliance period to avoid re-delisting.
- Neuro-Kinesis Acquisition: Assess the likelihood of closing the proposed acquisition and the associated cash inflow, noting the LOI is non-binding.
- Internal Control Remediation: Review the progress of the remediation plan for material weaknesses in financial reporting controls scheduled for 2025.
- Preferred Stock Terms: Review the specific triggering events for the Series C Preferred Stock redemption, which could require cash payments the company may not have.